ijms-logo

Journal Browser

Journal Browser

From Diagnosis to Treatment of Haematological Neoplasms

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 883

Special Issue Editors


E-Mail Website
Guest Editor
Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
Interests: surgical pathology; hematopathology; lymphomas; molecular pathology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy
Interests: hematopathology; immunohistochemistry; lymphoid neoplasms; myeloid neoplasms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Several editions of the World Health Organization (WHO) classifications of haematopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for diagnosis.

Since the 4th WHO edition in 2017, significant clinico-pathological, immunophenotypic and molecular advances have been made in the field of hematopoietic neoplasms, contributing to refining diagnostic criteria of several diseases to upgrade entities previously defined as provisional and to identify new entities.

This work resulted in the two recent classifying proposals of hematopoietic neoplasms, the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5).

We are pleased to invite you to submit your research papers to this Special Issue, which aims to shape the current landscape of the diagnosis and treatment of haematological neoplasms of both myeloid and lymphoid origin by critically assessing the more recent technological advances in the recognition of novel entities, the detection of prognostic and predictive biomarkers, and the application of precision medicine tools.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) ancillary techniques (including immunohistochemistry, PCR-based methods, and cytogenetics), the identification of prognostic/predictive biomarkers, issues in the diagnosis/differential diagnosis of challenging entities, and the current role of pathology in tailored therapy and precision medicine.

We look forward to receiving your contributions.

Dr. Magda Zanelli
Dr. Francesca Sanguedolce
Dr. Stefano Ascani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • haematological neoplasms
  • biomarkers
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1165 KiB  
Article
T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia
by Fatemah S. Basingab, Manar Bashanfer, Aisha A. Alrofaidi, Ahmed S. Barefah, Rawan Hammad, Hadil M. Alahdal, Jehan S. Alrahimi, Kawther A. Zaher, Sabah Hassan, Ali H. Algiraigri, Mai M. El-Daly, Saleh A. Alkarim and Alia M. Aldahlawi
Int. J. Mol. Sci. 2024, 25(20), 11148; https://doi.org/10.3390/ijms252011148 - 17 Oct 2024
Viewed by 722
Abstract
B-cell acute lymphoblastic leukemia (B-ALL) accounts for 85% of all childhood ALL. Malignancies exhaust T and B cells, resulting in an increased expression of immune checkpoint receptors (ICRs), such as T-cell immunoglobulin and mucin domain 3 (TIM-3). TIM-3 has been found to be [...] Read more.
B-cell acute lymphoblastic leukemia (B-ALL) accounts for 85% of all childhood ALL. Malignancies exhaust T and B cells, resulting in an increased expression of immune checkpoint receptors (ICRs), such as T-cell immunoglobulin and mucin domain 3 (TIM-3). TIM-3 has been found to be dysregulated in different types of cancer. However, there is a lack of rigorous studies on the TIM-3 expression in B-ALL. The current study aimed to measure the expression of TIM-3 at the gene and protein levels and evaluate the potential of TIM-3 as a biomarker in B-ALL. A total of 28 subjects were recruited between 2021 and 2023, comprising 18 subjects diagnosed with B-ALL and 10 non-malignant healthy controls. The B-ALL patients were divided into three groups: newly diagnosed (four patients), in remission (nine patients), and relapse/refractory (five patients). The expression levels of TIM-3 were evaluated using the real-time qPCR and ELISA techniques. The results revealed that the TIM-3 expression was significantly downregulated in the malignant B-ALL patients compared to the non-malignant healthy controls in the mRNA (FC = −1.058 ± 0.3548, p = 0.0061) and protein blood serum (p = 0.0498) levels. A significant TIM-3 gene reduction was observed in the relapse/refractory cases (FC = −1.355 ± 0.4686, p = 0.0327). TIM-3 gene expression allowed for significant differentiation between patients with malignant B-ALL and non-malignant healthy controls, with an area under the curve (AUC) of 0.706. The current study addressed the potential of reduced levels of TIM-3 as a negative biomarker for B-ALL patients. Full article
(This article belongs to the Special Issue From Diagnosis to Treatment of Haematological Neoplasms)
Show Figures

Figure 1

Back to TopTop